69 citations
,
February 2008 in “The American journal of pathology” This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.
415 citations
,
January 2008 in “Cell” NFATc1 controls hair stem cell activity, affecting hair growth and could be a target for hair loss treatments.
143 citations
,
January 2007 in “The American Journal of Human Genetics” This study identified four genetic loci on chromosomes 6, 10, 16, and 18 that may contribute to susceptibility for alopecia areata and suggested shared genetic factors with psoriasis.
13 citations
,
December 2006 in “Journal of experimental animal science” This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.
100 citations
,
July 2006 in “British Journal of Dermatology” This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.
18 citations
,
October 2005 in “International Journal of Pharmaceutics” This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.
36 citations
,
May 2005 in “BMC dermatology” This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.
29 citations
,
January 2004 in “Experimental Dermatology” In this study, anthralin treatment led to hair regrowth in alopecia areata-like affected C3H/HeJ mice, suggesting it may be an effective therapy for this condition.
12 citations
,
November 2003 in “Journal of the American Academy of Dermatology” This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.
17 citations
,
September 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.
23 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This review discusses rodent models of alopecia areata and suggests they are crucial for understanding the autoimmune mechanisms and potential treatments but reports no new clinical results.
19 citations
,
March 2003 in “Journal of Investigative Dermatology” This study found that mechlorethamine restored hair growth in mice with alopecia-areata-like disease by eliminating infiltrated lymphocytes and inhibiting certain pro-inflammatory cytokines in treated skin areas.
61 citations
,
February 2003 in “Experimental Dermatology” This study found that increasing dietary soy oil content reduced alopecia areata development in C3H/HeJ mice, though genistein injection showed no significant effect.
114 citations
,
August 2002 in “Journal of Investigative Dermatology” Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.
69 citations
,
July 2002 in “Clinical and Experimental Dermatology” This review discusses rodent models of alopecia areata and highlights genetic and epigenetic factors influencing its development, but reports no new experimental results.
77 citations
,
June 2002 in “Journal of Investigative Dermatology” CD44 variant changes start alopecia areata, but don't maintain it.
30 citations
,
December 2001 in “Experimental dermatology” This study found that gonadal steroid hormones influence alopecia areata in C3H/HeJ mice, with estradiol promoting progression and dihydrotestosterone conferring resistance to disease onset.
41 citations
,
February 2001 in “Current pharmaceutical design” This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.
71 citations
,
February 2000 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.
131 citations
,
November 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that alopecia areata can be induced and serially transferred in C3H/HeJ mice using skin grafts, providing a useful model for studying the disease in humans.
11 citations
,
July 1998 in “Journal of Investigative Dermatology” β-estradiol slows hair growth in mice.
118 citations
,
April 1998 in “Dermatologic Clinics” This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.
71 citations
,
January 1998 in “Pathobiology” This review discusses the use of animal models to study alopecia areata and reports no new experimental results, emphasizing the potential for these models to explore the disease's genetics and treatment.
72 citations
,
September 1997 in “Journal of Investigative Dermatology” 150 citations
,
April 1997 in “Journal of Investigative Dermatology” 11 citations
,
April 1997 in “International Journal of Dermatology” This article discusses using topical tretinoin with intralesional triamcinolone acetonide for alopecia areata in northern Saudi Arabia, but it reports no new clinical findings.
154 citations
,
October 1996 in “Proceedings of the National Academy of Sciences of the United States of America” This study found that 17-beta-estradiol inhibits hair growth in mice by blocking hair follicles in the telogen phase, whereas an estrogen receptor antagonist promotes hair growth by initiating anagen.
91 citations
,
March 1996 in “Archives of Dermatological Research” This study concluded that cytokines and growth factors significantly regulate hair growth in vitro, with some completely inhibiting growth, such as EGF and TNFα.
124 citations
,
August 1994 in “Journal of Investigative Dermatology” This study found that applying dexamethasone to mice induced catagen-like follicle changes significantly earlier and more consistently than a vehicle, such changes being useful for studying hair follicle regression.
54 citations
,
July 1994 in “Journal of Dermatological Science” This study found that topical application of FK506 stimulated hair growth in animals, which may occur independently of its immunosuppressive effects, though its effect on human hair growth remains unclear.
178 citations
,
June 1994 in “Journal of Investigative Dermatology” This study found that a non-scarring alopecia in C3H/HeJ mice resembles human alopecia areata and may serve as a valuable model for studying specific subtypes of the human condition.
41 citations
,
November 1993 in “Journal of The American Academy of Dermatology” This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.
55 citations
,
June 1987 in “PubMed” In this study, cyclosporin A treatment significantly increased hair length in nude mice compared to controls, but hair growth reversed after treatment stopped.
78 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil promotes hair growth but stops working when discontinued.
95 citations
,
December 1980 in “The New England Journal of Medicine” Minoxidil helped bald patient regrow hair.
100 citations
,
March 1973 in “American Journal of Cardiology” Minoxidil effectively lowers blood pressure without major side effects.
75 citations
,
September 1971 in “British Journal of Dermatology” This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.